Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Lupin Launches Generic Sugammadex Injection in US Market

Guavy AI Editorial Team
Instruments
MRK
Share

Lupin Limited has launched its generic Sugammadex Injection in the US market following approval from the FDA for its Abbreviated New Drug Application (ANDA).

The company introduced Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials, which are bioequivalent to Bridion Injection of Merck, Sharp & Dohme LLC.

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged two years and older undergoing surgery.

More on Stocks

Stocks just now

Earnings and Jobs Reports to Dominate Wall Street Week

Stocks 7m ago

Chevron Posts Record Earnings as Oil Prices Soar

Stocks 7m ago

Chevron Eyes 50% Venezuelan Output Growth by 2028 Amid Middle East Conflict

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy